Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


04.02.2019

1 Ann Oncol
2 Ann Thorac Surg
1 Arch Bronconeumol
3 BMC Cancer
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
1 Cancer Res
4 Carcinogenesis
6 Clin Lung Cancer
1 Clin Nucl Med
1 Eur Respir J
3 Int J Cancer
1 Int J Oncol
2 J Cancer Res Clin Oncol
1 J Clin Invest
2 J Natl Cancer Inst
1 J Thorac Cardiovasc Surg
4 J Thorac Oncol
1 Mol Carcinog
1 Oncogene
2 Oncol Rep
1 Oncologist
1 PLoS Comput Biol
4 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. ZUO H, Ueland PM, Midttun O, Tell GS, et al
    Vitamin B6 catabolism and lung cancer risk: results from the Lung Cancer Cohort Consortium (LC3).
    Ann Oncol. 2019 Jan 30. pii: 5304407. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  2. VAN DER LEEDEN M, Balland C, Geleijn E, Huijsmans RJ, et al
    In-hospital mobilization, physical fitness and physical functioning following lung cancer surgery.
    Ann Thorac Surg. 2019 Jan 25. pii: S0003-4975(19)30116.
    PubMed     Text format     Abstract available

  3. DING H, Wang H, Xu L, Song N, et al
    Survival and resected lymph nodes number during sublobectomy for N0 Non-Small Cell Lung Cancer </= 2cm.
    Ann Thorac Surg. 2019 Jan 22. pii: S0003-4975(19)30083.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  4. DE VEGA SANCHEZ B, Disdier Vicente C, Martinez Garcia G
    Tracheobronchial Amyloidosis as an Incidental Finding in a Patient With Lung Cancer.
    Arch Bronconeumol. 2019 Jan 22. pii: S0300-2896(18)30470.
    PubMed     Text format    


    BMC Cancer

  5. LAVACCHI D, Nobili S, Brugia M, Paderi A, et al
    A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma.
    BMC Cancer. 2018;18:1024.
    PubMed     Text format     Abstract available

  6. IMAKITA T, Matsumoto H, Hirano K, Morisawa T, et al
    Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review.
    BMC Cancer. 2019;19:105.
    PubMed     Text format     Abstract available

  7. HAI Y, Chen N, Wu W, Wang Z, et al
    High postoperative monocyte indicates inferior Clinicopathological characteristics and worse prognosis in lung adenocarcinoma or squamous cell carcinoma after lobectomy.
    BMC Cancer. 2018;18:1011.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  8. ZHU Y, Wei Y, Zhang R, Dong X, et al
    Elevated platelet count appears to be causally associated with increased risk of lung cancer: A Mendelian randomization analysis.
    Cancer Epidemiol Biomarkers Prev. 2019 Jan 30. pii: 1055-9965.EPI-18-0356.
    PubMed     Text format     Abstract available


    Cancer Lett

  9. LIU X, Min S, Wu N, Liu H, et al
    miR-193a-3p inhibition of the Slug activator PAK4 suppresses non-small cell lung cancer aggressiveness via the p53/Slug/L1CAM pathway.
    Cancer Lett. 2019;447:56-65.
    PubMed     Text format     Abstract available

  10. NEGI H, Merugu SB, Mangukiya HB, Li Z, et al
    Anterior Gradient-2 Monoclonal Antibody Inhibits Lung Cancer Growth and Metastasis by Upregulating p53 Pathway and Without Exerting Any Toxicological Effects: A Preclinical Study.
    Cancer Lett. 2019 Jan 24. pii: S0304-3835(19)30045.
    PubMed     Text format     Abstract available


    Cancer Res

  11. JIANG Y, Chen T, Wang T, Liang W, et al
    PAK4 phosphorylates fumarase and blocks TGF-beta-induced cell growth arrest in lung cancer cells.
    Cancer Res. 2019 Jan 25. pii: 0008-5472.CAN-18-2575.
    PubMed     Text format     Abstract available


    Carcinogenesis

  12. SONG JM, Upadhyaya P, Kassie F
    Nitric oxide-donating aspirin (NO-Aspirin) suppresses lung tumorigenesis in vitro and in vivo and these effects are associated with modulation of the EGFR signaling pathway.
    Carcinogenesis. 2018;39:911-920.
    PubMed     Text format     Abstract available

  13. ALHAMDOW A, Lindh C, Hagberg J, Graff P, et al
    DNA methylation of the cancer-related genes F2RL3 and AHRR is associated with occupational exposure to polycyclic aromatic hydrocarbons.
    Carcinogenesis. 2018;39:869-878.
    PubMed     Text format     Abstract available

  14. JANG JH, Janker F, De Meester I, Arni S, et al
    The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity.
    Carcinogenesis. 2019 Jan 29. pii: 5303986. doi: 10.1093.
    PubMed     Text format     Abstract available

  15. FAN J, Zhu M, Wang Y, Li Z, et al
    Genome-wide analysis of expression quantitative trait loci identified potential lung cancer susceptibility variants among Asian populations.
    Carcinogenesis. 2019 Jan 23. pii: 5299334. doi: 10.1093.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  16. PARK W, Lopes G
    Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2018 Dec 19. pii: S1525-7304(18)30327.
    PubMed     Text format     Abstract available

  17. LEE J, Sun JM, Lee SH, Ahn JS, et al
    Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Clin Lung Cancer. 2018 Dec 31. pii: S1525-7304(18)30357.
    PubMed     Text format     Abstract available

  18. WHEATLEY-PRICE P, Gadgeel S, Takahashi T, Li X, et al
    Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2018 Nov 29. pii: S1525-7304(18)30308.
    PubMed     Text format     Abstract available

  19. PACHECO J, Bunn PA
    Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133.
    Clin Lung Cancer. 2019 Jan 2. pii: S1525-7304(18)30356.
    PubMed     Text format     Abstract available

  20. WANG B, Gao Y, Huang Y, Ou Q, et al
    Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2018 Dec 31. pii: S1525-7304(18)30354.
    PubMed     Text format    

  21. BEAU-FALLER M, Texier M, Blons H, Richard N, et al
    Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).
    Clin Lung Cancer. 2018 Dec 19. pii: S1525-7304(18)30336.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  22. TIAN T, Chen Y, Xiang Y, Liu L, et al
    Remarkable Response of Pulmonary Metastases Rather Than Remnant Thyroid in 131I Therapy of Follicular Thyroid Cancer.
    Clin Nucl Med. 2019 Jan 25. doi: 10.1097/RLU.0000000000002477.
    PubMed     Text format     Abstract available


    Eur Respir J

  23. VAN MEERBEECK JP, Jansen G, Giovannetti E, Peters GJ, et al
    Aminopeptidase antibodies in mesothelioma: new wine deserves new sacks.
    Eur Respir J. 2018;51.
    PubMed     Text format    


    Int J Cancer

  24. LI W, Sparidans RW, Wang Y, Lebre MC, et al
    P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
    Int J Cancer. 2018;143:2029-2038.
    PubMed     Text format     Abstract available

  25. OH E, Kim YJ, An H, Sung D, et al
    Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31585.
    PubMed     Text format     Abstract available

  26. VON NEUBECK B, Gondi G, Riganti C, Pan C, et al
    An inhibitory antibody targeting Carbonic Anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.
    Int J Cancer. 2018 May 22. doi: 10.1002/ijc.31607.
    PubMed     Text format     Abstract available


    Int J Oncol

  27. KATO T, Jin CS, Lee D, Ujiie H, et al
    Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
    Int J Oncol. 2018;53:2034-2046.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  28. LIU C, Li Z, Wang S, Fan Y, et al
    FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2019;145:65-76.
    PubMed     Text format     Abstract available

  29. ZHANG J, Xiang C, Han Y, Teng H, et al
    Differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma with the assistance of next-generation sequencing and immunohistochemistry.
    J Cancer Res Clin Oncol. 2019;145:269-279.
    PubMed     Text format     Abstract available


    J Clin Invest

  30. ZHAO G, Gong L, Su D, Jin Y, et al
    Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin beta1.
    J Clin Invest. 2019 Jan 28. pii: 122779. doi: 10.1172/JCI122779.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  31. STRAM DO, Park SL, Haiman CA, Murphy SE, et al
    Racial/Ethnic Differences in Lung Cancer Incidence in the Multiethnic Cohort Study: An Update.
    J Natl Cancer Inst. 2019 Jan 28. pii: 5303811. doi: 10.1093.
    PubMed     Text format     Abstract available

  32. RAI A, Doria-Rose VP, Silvestri GA, Yabroff KR, et al
    Evaluating Lung Cancer Screening Uptake, Outcomes, and Costs in the United States: Challenges With Existing Data and Recommendations for Improvement.
    J Natl Cancer Inst. 2019 Jan 30. pii: 5304457. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  33. WOLF A, Alpert N, Tran BV, Liu B, et al
    Persistence of racial disparities in early-stage lung cancer treatment.
    J Thorac Cardiovasc Surg. 2018 Dec 11. pii: S0022-5223(18)33258.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  34. VARKARIS A, Sehgal K, Rangachari D, Costa DB, et al
    Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer.
    J Thorac Oncol. 2019;14:e34-e36.
    PubMed     Text format    

  35. WATANABE K, Kage H, Shinozaki-Ushiku A, Kohsaka S, et al
    Spontaneous Transdifferentiation from Small Cell Lung Carcinoma to Squamous Cell Carcinoma.
    J Thorac Oncol. 2019;14:e31-e34.
    PubMed     Text format    

  36. BOGART JA, Mix M
    Management of the Brain in Small Cell Lung Cancer: Are Patients Paying a Lot Now Instead of a Little Later?
    J Thorac Oncol. 2019;14:153-156.
    PubMed     Text format    

  37. TABBO F, D'Aveni A, Tota D, Pignataro D, et al
    Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase-Positive Lung Cancer Patient: Adverse Event or Disease Spread?
    J Thorac Oncol. 2019;14:e38-e40.
    PubMed     Text format    


    Mol Carcinog

  38. LI Y, Xiang C, Shen N, Deng L, et al
    Functional polymorphisms on chromosome 5p15.33 disturb telomere biology and confer the risk of non-small cell lung cancer in Chinese population.
    Mol Carcinog. 2019 Jan 25. doi: 10.1002/mc.22980.
    PubMed     Text format     Abstract available


    Oncogene

  39. CAO J, Zhu Z, Wang H, Nichols TC, et al
    Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.
    Oncogene. 2019 Jan 30. pii: 10.1038/s41388-019-0708.
    PubMed     Text format     Abstract available


    Oncol Rep

  40. CHEN P, Gu YY, Ma FC, He RQ, et al
    Expression levels and cotargets of miRNA1263p and miRNA1265p in lung adenocarcinoma tissues: Alphan exploration with RTqPCR, microarray and bioinformatic analyses.
    Oncol Rep. 2019;41:939-953.
    PubMed     Text format     Abstract available

  41. KOBAYASHI S, Saio M, Fukuda T, Kimura K, et al
    Image analysis of the nuclear characteristics of emerin protein and the correlation with nuclear grooves and intranuclear cytoplasmic inclusions in lung adenocarcinoma.
    Oncol Rep. 2019;41:133-142.
    PubMed     Text format     Abstract available


    Oncologist

  42. PARK H, Dahlberg SE, Lydon CA, Araki T, et al
    M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.
    Oncologist. 2019 Jan 29. pii: theoncologist.2018-0596.
    PubMed     Text format     Abstract available


    PLoS Comput Biol

  43. BISMEIJER T, Canisius S, Wessels LFA
    Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis.
    PLoS Comput Biol. 2018;14:e1006520.
    PubMed     Text format     Abstract available


    PLoS One

  44. KIM Y, Lee D, Lee J, Lee S, et al
    Role of tumor-associated neutrophils in regulation of tumor growth in lung cancer development: A mathematical model.
    PLoS One. 2019;14:e0211041.
    PubMed     Text format     Abstract available

  45. MUENCH D, Rezzoug F, Thomas SD, Xiao J, et al
    Quadruplex-forming oligonucleotide targeted to the VEGF promoter inhibits growth of non-small cell lung cancer cells.
    PLoS One. 2019;14:e0211046.
    PubMed     Text format     Abstract available

  46. BOSSCHIETER J, Bach S, Bijnsdorp IV, Segerink LI, et al
    A protocol for urine collection and storage prior to DNA methylation analysis.
    PLoS One. 2018;13:e0200906.
    PubMed     Text format     Abstract available

  47. CHEN J
    The prognostic analysis of different metastatic patterns in advanced liver cancer patients: A population based analysis.
    PLoS One. 2018;13:e0200909.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: